Results 151 to 160 of about 5,029 (250)

Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis‐Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Among 211 prospectively followed Swiss patients with eosinophilic oesophagitis, chronic rhinosinusitis was two‐ to three‐fold more common than in the general population. It was associated with greater oesophageal symptom severity and, in a quarter of cases, was experienced by patients as more debilitating than the underlying oesophageal disease ...
Gebhardt Aidan   +52 more
wiley   +1 more source

He was only thirty one. [PDF]

open access: yesPalliat Support Care
Shapoo N, Boma N.
europepmc   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos   +4 more
wiley   +1 more source

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

open access: yesBritish Journal of Haematology, EarlyView.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard   +10 more
wiley   +1 more source

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Home - About - Disclaimer - Privacy